Binding-induced fibrillogenesis peptide inhibits RANKL-mediated osteoclast activation against osteoporosis

• Published in: Biomaterials Vol. 302; p. 122331
• Main Authors: Liang, Qi-Lin, Xu, Huan-Ge, Yu, Long, Ding, Meng-Ru, Li, Yu-Ting, Qi, Gao-Feng, Zhang, Kuo, Wang, Lei, Wang, Hao, Cui, Xu
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.11.2023
• Subjects: Binding-induced fibrillogenesis; Osteoporosis; Peptide; RANKL; Self-assembly; Osteoporosis; Self-assembly; RANKL; Binding-induced fibrillogenesis; Peptide
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2023.122331

Osteoporosis is primarily driven by an imbalance between bone resorption and formation, stemming from enhanced osteoclast activity during bone remodeling. At the crux of this mechanism lies the pivotal RANK-RANKL-OPG axis. In our study, we designed two binding-induced fibrillogenesis (BIF) peptides, namely BIFP and BIFY, targeting RANK and RANKL, respectively. These BIF peptides, with distinct hydrophilic and hydrophobic characteristics, assemble into nanoparticles (NPs) in aqueous solution. Through specific ligand-receptor interactions, these NPs efficiently target and bind to specific proteins, resulting in the formation of fibrous networks that effectively inhibit the RANK-RANKL associations. Experiments have confirmed the potent inhibitory effects of peptides on both osteoclast differentiation and function. Compared with the +RANKL controls, BIFP and BIFY demonstrated a more remarkable reduction in tartrate resistant acid phosphatase (TRAP)-positive cells, achieving an impressive decline of 82.8% and 70.7%, respectively. Remarkably, the administration of BIFP led to a substantial reduction in bone resorption pit area by 17.4%, compared to a significant increase of 92.4% in the +RANKL groups. In vivo experiments on an ovariectomized mouse model demonstrated that the BIFP treated group exhibited an impressive 2.6-fold elevation in bone mineral density and an astounding 4.0-fold enhancement in bone volume/total volume as against those of the PBS-treated group. Overall, BIF peptides demonstrate remarkable abilities to impede osteoclast differentiation, presenting promising prospects for the treatment of osteoporosis.